Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis release_rev_ee2f6a47-dc52-4e68-a0d6-aedb8c3bb252

by Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang

Entity Metadata (schema)

abstracts[] {'sha1': 'acf706c9ce78f0205560693c167e57e259d5ead7', 'content': '<jats:sec id="sec001">\n<jats:title>Background</jats:title>\nNumerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19), but the results are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective.\n</jats:sec>\n<jats:sec id="sec002">\n<jats:title>Methods and findings</jats:title>\nWe carried out a systematic review and network meta-analysis (NMA) to systematically evaluate the comparative efficacy and safety of pharmacological interventions and the level of evidence behind each treatment regimen in different clinical settings. Both published and unpublished randomized controlled trials (RCTs) and confounding-adjusted observational studies which met our predefined eligibility criteria were collected. We included studies investigating the effect of pharmacological management of patients hospitalized for COVID-19 management. Mild patients who do not require hospitalization or have self-limiting disease courses were not eligible for our NMA. A total of 110 studies (40 RCTs and 70 observational studies) were included. PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/" xlink:type="simple">ClinicalTrials.gov</jats:ext-link> were searched from the beginning of 2020 to August 24, 2020. Studies from Asia (41 countries, 37.2%), Europe (28 countries, 25.4%), North America (24 countries, 21.8%), South America (5 countries, 4.5%), and Middle East (6 countries, 5.4%), and additional 6 multinational studies (5.4%) were included in our analyses. The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events. Based on RCTs, the risk of progression to severe course and mortality was significantly reduced with corticosteroids (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.06 to 0.86, <jats:italic>p</jats:italic> = 0.032, and OR 0.78, 95% CI 0.66 to 0.91, <jats:italic>p</jats:italic> = 0.002, respectively) and remdesivir (OR 0.29, 95% CI 0.17 to 0.50, <jats:italic>p</jats:italic> &lt; 0.001, and OR 0.62, 95% CI 0.39 to 0.98, <jats:italic>p</jats:italic> = 0.041, respectively) compared to standard care for moderate to severe COVID-19 patients in non-ICU; corticosteroids were also shown to reduce mortality rate (OR 0.54, 95% CI 0.40 to 0.73, <jats:italic>p</jats:italic> &lt; 0.001) for critically ill patients in ICU. In analyses including observational studies, interferon-alpha (OR 0.05, 95% CI 0.01 to 0.39, <jats:italic>p</jats:italic> = 0.004), itolizumab (OR 0.10, 95% CI 0.01 to 0.92, <jats:italic>p</jats:italic> = 0.042), sofosbuvir plus daclatasvir (OR 0.26, 95% CI 0.07 to 0.88, <jats:italic>p</jats:italic> = 0.030), anakinra (OR 0.30, 95% CI 0.11 to 0.82, <jats:italic>p</jats:italic> = 0.019), tocilizumab (OR 0.43, 95% CI 0.30 to 0.60, <jats:italic>p</jats:italic> &lt; 0.001), and convalescent plasma (OR 0.48, 95% CI 0.24 to 0.96, <jats:italic>p</jats:italic> = 0.038) were associated with reduced mortality rate in non-ICU setting, while high-dose intravenous immunoglobulin (IVIG) (OR 0.13, 95% CI 0.03 to 0.49, <jats:italic>p</jats:italic> = 0.003), ivermectin (OR 0.15, 95% CI 0.04 to 0.57, <jats:italic>p</jats:italic> = 0.005), and tocilizumab (OR 0.62, 95% CI 0.42 to 0.90, <jats:italic>p</jats:italic> = 0.012) were associated with reduced mortality rate in critically ill patients. Convalescent plasma was the only treatment option that was associated with improved viral clearance rate at 2 weeks compared to standard care (OR 11.39, 95% CI 3.91 to 33.18, <jats:italic>p</jats:italic> &lt; 0.001). The combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence (OR 2.01, 95% CI 1.26 to 3.20, <jats:italic>p</jats:italic> = 0.003) and fatal cardiac complications in cardiac-impaired populations (OR 2.23, 95% CI 1.24 to 4.00, <jats:italic>p</jats:italic> = 0.007). No drug was significantly associated with increased noncardiac serious adverse events compared to standard care. The quality of evidence of collective outcomes were estimated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The major limitation of the present study is the overall low level of evidence that reduces the certainty of recommendations. Besides, the risk of bias (RoB) measured by RoB2 and ROBINS-I framework for individual studies was generally low to moderate. The outcomes deducted from observational studies could not infer causality and can only imply associations. The study protocol is publicly available on PROSPERO (CRD42020186527).\n</jats:sec>\n<jats:sec id="sec003">\n<jats:title>Conclusions</jats:title>\nIn this NMA, we found that anti-inflammatory agents (corticosteroids, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved outcomes of hospitalized COVID-19 patients. Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be translated to practice and policy; the remaining 71% are of low or very low certainty and warrant further studies to establish firm conclusions.\n</jats:sec>', 'mimetype': 'application/xml+jats', 'lang': None}
container {'state': 'active', 'ident': 'iznnn644szdwva7khyxqzc73bi', 'revision': '6511f755-9fb2-471e-8e54-f9dddcc83658', 'redirect': None, 'extra': {'abbrev': 'PLoS Med.', 'country': 'us', 'default_license': 'CC-BY', 'doaj': {'archive': ['PMC'], 'as_of': '2022-07-06', 'default_license': 'CC-BY', 'seal': True}, 'kbart': {'lockss': {'year_spans': [[2004, 2009]]}}, 'languages': ['en'], 'publisher_type': 'oa', 'road': {'as_of': '2018-01-24'}, 'sherpa_romeo': {'color': 'green'}, 'urls': ['https://journals.plos.org/plosmedicine/', 'http://www.plosmedicine.org/']}, 'edit_extra': None, 'name': 'PLoS Medicine', 'container_type': 'journal', 'publication_status': None, 'publisher': 'Public Library of Science', 'issnl': '1549-1277', 'issne': '1549-1676', 'issnp': '1549-1277', 'wikidata_qid': 'Q1686921'}
container_id iznnn644szdwva7khyxqzc73bi
contribs[] {'index': 0, 'creator_id': 'qirlxeyjefg7fbafyc6de37oyy', 'creator': None, 'raw_name': 'Min Seo Kim', 'given_name': 'Min Seo', 'surname': 'Kim', 'role': 'author', 'raw_affiliation': None, 'extra': {'seq': 'first'}}
{'index': 1, 'creator_id': 'kzsag6mk3rhdxe23exifgqeula', 'creator': None, 'raw_name': 'Min Ho An', 'given_name': 'Min Ho', 'surname': 'An', 'role': 'author', 'raw_affiliation': None, 'extra': None}
{'index': 2, 'creator_id': None, 'creator': None, 'raw_name': 'Won Jun Kim', 'given_name': 'Won Jun', 'surname': 'Kim', 'role': 'author', 'raw_affiliation': None, 'extra': None}
{'index': 3, 'creator_id': None, 'creator': None, 'raw_name': 'Tae-Ho Hwang', 'given_name': 'Tae-Ho', 'surname': 'Hwang', 'role': 'author', 'raw_affiliation': None, 'extra': None}
{'index': None, 'creator_id': None, 'creator': None, 'raw_name': 'Mirjam E. E. Kretzschmar', 'given_name': 'Mirjam E. E.', 'surname': 'Kretzschmar', 'role': 'editor', 'raw_affiliation': None, 'extra': {'seq': 'first'}}
ext_ids {'doi': '10.1371/journal.pmed.1003501', 'wikidata_qid': None, 'isbn13': None, 'pmid': '33378357', 'pmcid': None, 'core': None, 'arxiv': None, 'jstor': None, 'ark': None, 'mag': None, 'doaj': None, 'dblp': None, 'oai': None, 'hdl': None}
files
filesets
issue 12
language en
license_slug
number
original_title
pages e1003501
publisher Public Library of Science (PLoS)
refs[] {'index': 0, 'target_release_id': None, 'extra': {'authors': ['JP Higgins'], 'doi': '10.1016/s0140-6736(15)61478-7', 'issue': '9994', 'volume': '386'}, 'key': 'pmed.1003501.ref001', 'year': 2015, 'container_name': 'The Lancet', 'title': 'Network meta-analysis: a norm for comparative effectiveness?', 'locator': '628'}
{'index': 1, 'target_release_id': None, 'extra': {'authors': ['B Hutton'], 'doi': '10.7326/m14-2385', 'issue': '11', 'volume': '162'}, 'key': 'pmed.1003501.ref002', 'year': 2015, 'container_name': 'Ann Intern Med', 'title': 'The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations', 'locator': '777'}
{'index': 2, 'target_release_id': None, 'extra': {'authors': ['MS Kim']}, 'key': 'pmed.1003501.ref003', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis.', 'locator': None}
{'index': 3, 'target_release_id': None, 'extra': {'authors': ['M Huhn'], 'doi': '10.1016/s0140-6736(19)31135-3', 'issue': '10202', 'volume': '394'}, 'key': 'pmed.1003501.ref004', 'year': 2019, 'container_name': 'The Lancet', 'title': 'Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis', 'locator': '939'}
{'index': 4, 'target_release_id': None, 'extra': {'authors': ['A Slee'], 'doi': '10.1016/s0140-6736(18)31793-8', 'issue': '10173', 'volume': '393'}, 'key': 'pmed.1003501.ref005', 'year': 2019, 'container_name': 'The Lancet', 'title': 'Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis', 'locator': '768'}
{'index': 5, 'target_release_id': None, 'extra': {'authors': ['D Eyding'], 'doi': '10.1136/bmj.c4737', 'volume': '341'}, 'key': 'pmed.1003501.ref006', 'year': 2010, 'container_name': 'BMJ', 'title': 'Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials', 'locator': 'c4737'}
{'index': 6, 'target_release_id': None, 'extra': {'authors': ['P Jinatongthai'], 'doi': '10.1016/s0140-6736(17)31441-1', 'issue': '10096', 'volume': '390'}, 'key': 'pmed.1003501.ref007', 'year': 2017, 'container_name': 'The Lancet', 'title': 'Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis', 'locator': '747'}
{'index': 7, 'target_release_id': None, 'extra': {'authors': ['P Langhorne']}, 'key': 'pmed.1003501.ref008', 'year': 2020, 'container_name': 'Cochrane Database Syst Rev', 'title': 'Organised inpatient (stroke unit) care for stroke: network meta-analysis.', 'locator': None}
{'index': 8, 'target_release_id': None, 'extra': {'authors': ['L Wynants'], 'volume': '369'}, 'key': 'pmed.1003501.ref009', 'year': 2020, 'container_name': 'BMJ', 'title': 'Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal', 'locator': None}
{'index': 9, 'target_release_id': None, 'extra': {'authors': ['J-W Li'], 'doi': '10.1016/j.pcad.2020.04.008', 'volume': '63'}, 'key': 'pmed.1003501.ref010', 'year': 2020, 'container_name': 'Prog Cardiovasc Dis.', 'title': 'The impact of 2019 novel coronavirus on heart injury: A systemic review and Meta-analysis.', 'locator': '518'}
{'index': 10, 'target_release_id': None, 'extra': {'authors': ['S Sultan'], 'doi': '10.1053/j.gastro.2020.05.001', 'volume': '159'}, 'key': 'pmed.1003501.ref011', 'year': 2020, 'container_name': 'Gastroenterology', 'title': 'AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19', 'locator': '320'}
{'index': 11, 'target_release_id': None, 'extra': {'authors': ['RM Viner'], 'doi': '10.1016/s2352-4642(20)30095-x'}, 'key': 'pmed.1003501.ref012', 'year': 2020, 'container_name': 'The Lancet Child & Adolescent Health.', 'title': 'School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review.', 'locator': '397'}
{'index': 12, 'target_release_id': None, 'extra': {'authors': ['O Efthimiou'], 'doi': '10.1002/sim.7223', 'volume': '36'}, 'key': 'pmed.1003501.ref013', 'year': 2017, 'container_name': 'Stat Med', 'title': 'Combining randomized and non-randomized evidence in network meta-analysis.', 'locator': '1210'}
{'index': 13, 'target_release_id': None, 'extra': {'authors': ['E Marconi'], 'doi': '10.1016/j.phrs.2019.104418'}, 'key': 'pmed.1003501.ref014', 'year': 2019, 'container_name': 'Pharmacol Res', 'title': 'Efficacy and safety of pharmacological treatments for Patent Ductus Arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies', 'locator': '104418'}
{'index': 14, 'target_release_id': None, 'extra': {'authors': ['AC Tricco'], 'doi': '10.1136/bmj.k4029', 'volume': '363'}, 'key': 'pmed.1003501.ref015', 'year': 2018, 'container_name': 'BMJ', 'title': 'Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis', 'locator': 'k4029'}
{'index': 15, 'target_release_id': None, 'extra': {'authors': ['C Zeng'], 'doi': '10.1136/bjsports-2017-098043', 'issue': '10', 'volume': '52'}, 'key': 'pmed.1003501.ref016', 'year': 2018, 'container_name': 'Br J Sports Med', 'title': 'Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.', 'locator': '642'}
{'index': 16, 'target_release_id': None, 'extra': {'authors': ['C Zhang'], 'doi': '10.1371/journal.pmed.1003130', 'volume': '17'}, 'key': 'pmed.1003501.ref017', 'year': 2020, 'container_name': 'PLoS Med.', 'title': 'Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series.', 'locator': 'e1003130'}
{'index': 17, 'target_release_id': None, 'extra': {'authors': ['J Toubiana'], 'volume': '369'}, 'key': 'pmed.1003501.ref018', 'year': 2020, 'container_name': 'BMJ', 'title': 'Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study', 'locator': None}
{'index': 18, 'target_release_id': None, 'extra': {'authors': ['LR Feldstein'], 'doi': '10.1056/nejmoa2021680', 'volume': '383'}, 'key': 'pmed.1003501.ref019', 'year': 2020, 'container_name': 'N Engl J Med', 'title': 'Multisystem inflammatory syndrome in US children and adolescents', 'locator': '334'}
{'index': 19, 'target_release_id': None, 'extra': {'authors': ['G Wells']}, 'key': 'pmed.1003501.ref020', 'year': 2012, 'container_name': 'Ottawa Hospital Research Institute', 'title': 'The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses.', 'locator': None}
{'index': 20, 'target_release_id': None, 'extra': {'authors': ['HD Clark'], 'doi': '10.1016/s0197-2456(99)00026-4', 'volume': '20'}, 'key': 'pmed.1003501.ref021', 'year': 1999, 'container_name': 'Control Clin Trials', 'title': 'Assessing the quality of randomized trials: reliability of the Jadad scale.', 'locator': '448'}
{'index': 21, 'target_release_id': None, 'extra': {'authors': ['JA Sterne'], 'doi': '10.1136/bmj.i4919', 'volume': '355'}, 'key': 'pmed.1003501.ref022', 'year': 2016, 'container_name': 'BMJ', 'title': 'ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions', 'locator': 'i4919'}
{'index': 22, 'target_release_id': None, 'extra': {'authors': ['MA Puhan'], 'doi': '10.1136/bmj.g5630', 'volume': '349'}, 'key': 'pmed.1003501.ref023', 'year': 2014, 'container_name': 'BMJ', 'title': 'A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis', 'locator': 'g5630'}
{'index': 23, 'target_release_id': None, 'extra': {'authors': ['A Chaimani'], 'doi': '10.1371/journal.pone.0076654', 'issue': '10'}, 'key': 'pmed.1003501.ref024', 'year': 2013, 'container_name': 'Plos ONE', 'title': 'Graphical tools for network meta-analysis in STATA.', 'locator': 'e76654'}
{'index': 24, 'target_release_id': None, 'extra': {'authors': ['C Xu'], 'doi': '10.1111/jebm.12264', 'volume': '11'}, 'key': 'pmed.1003501.ref025', 'year': 2018, 'container_name': 'J Evid Based Med', 'title': 'Software and package applicating for network meta-analysis: A usage-based comparative study.', 'locator': '176'}
{'index': 25, 'target_release_id': None, 'extra': {'authors': ['S Shim'], 'doi': '10.4178/epih.e2017047', 'volume': '39'}, 'key': 'pmed.1003501.ref026', 'year': 2017, 'container_name': 'Epidemiol Health.', 'title': 'Network meta-analysis: application and practice using Stata.', 'locator': None}
{'index': 26, 'target_release_id': None, 'extra': {'authors': ['B Neupane'], 'doi': '10.1371/journal.pone.0115065', 'issue': '12'}, 'key': 'pmed.1003501.ref027', 'year': 2014, 'container_name': 'Plos ONE.', 'title': 'Network meta-analysis using R: a review of currently available automated packages.', 'locator': 'e115065'}
{'index': 27, 'target_release_id': None, 'extra': {'authors': ['MS Kim'], 'doi': '10.1016/j.jpsychires.2020.03.012', 'volume': '125'}, 'key': 'pmed.1003501.ref028', 'year': 2020, 'container_name': 'J Psychiatr Res', 'title': 'Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis', 'locator': '164'}
{'index': 28, 'target_release_id': None, 'extra': {'authors': ['HC Rhim']}, 'key': 'pmed.1003501.ref029', 'year': 2020, 'container_name': 'Orthop J Sports Med.', 'title': 'Comparative Efficacy and Tolerability of Nonsurgical Therapies for the Treatment of Midportion Achilles Tendinopathy: A Systematic Review With Network Meta-analysis.', 'locator': '2325967120930567'}
{'index': 29, 'target_release_id': None, 'extra': {'authors': ['SP Hozo'], 'doi': '10.1186/1471-2288-5-13'}, 'key': 'pmed.1003501.ref030', 'year': 2005, 'container_name': 'BMC Med Res Methodol.', 'title': 'Estimating the mean and variance from the median, range, and the size of a sample.', 'locator': '13'}
{'index': 30, 'target_release_id': None, 'extra': {'authors': ['X Wan'], 'doi': '10.1186/1471-2288-14-135', 'volume': '14'}, 'key': 'pmed.1003501.ref031', 'year': 2014, 'container_name': 'BMC Med Res Methodol', 'title': 'Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.', 'locator': '135'}
{'index': 31, 'target_release_id': None, 'extra': {'authors': ['T. Lumley'], 'doi': '10.1002/sim.1201', 'issue': '16', 'volume': '21'}, 'key': 'pmed.1003501.ref032', 'year': 2002, 'container_name': 'Stat Med.', 'title': 'Network meta-analysis for indirect treatment comparisons.', 'locator': '2313'}
{'index': 32, 'target_release_id': None, 'extra': {'authors': ['J Higgins'], 'doi': '10.1002/sim.1186', 'issue': '11', 'volume': '21'}, 'key': 'pmed.1003501.ref033', 'year': 2002, 'container_name': 'Stat Med', 'title': 'Quantifying heterogeneity in a meta-analysis.', 'locator': '1539'}
{'index': 33, 'target_release_id': None, 'extra': {'authors': ['U Krahn'], 'doi': '10.1186/1471-2288-13-35', 'volume': '13'}, 'key': 'pmed.1003501.ref034', 'year': 2013, 'container_name': 'BMC Med Res Methodol', 'title': 'A graphical tool for locating inconsistency in network meta-analyses.', 'locator': '35'}
{'index': 34, 'target_release_id': None, 'extra': {'authors': ['G Rücker'], 'doi': '10.1186/s12874-015-0060-8', 'volume': '15'}, 'key': 'pmed.1003501.ref035', 'year': 2015, 'container_name': 'BMC Med Res Methodol', 'title': 'Ranking treatments in frequentist network meta-analysis works without resampling methods.', 'locator': '58'}
{'index': 35, 'target_release_id': None, 'extra': {'authors': ['S Kanters'], 'doi': '10.1016/s2352-3018(17)30109-1', 'issue': '10'}, 'key': 'pmed.1003501.ref036', 'year': 2017, 'container_name': 'The Lancet HIV', 'title': 'Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis', 'locator': 'e433'}
{'index': 36, 'target_release_id': None, 'extra': {'authors': ['S Datta'], 'doi': '10.1016/s2214-109x(17)30201-2'}, 'key': 'pmed.1003501.ref037', 'year': 2017, 'container_name': 'Lancet Glob Health', 'title': 'Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysis', 'locator': 'e760'}
{'index': 37, 'target_release_id': None, 'extra': {'authors': ['C Cameron'], 'doi': '10.1186/s13643-015-0133-0'}, 'key': 'pmed.1003501.ref038', 'year': 2015, 'container_name': 'Syst Rev.', 'title': 'Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities.', 'locator': '147'}
{'index': 38, 'target_release_id': None, 'extra': {'authors': ['M Hoffmann']}, 'key': 'pmed.1003501.ref039', 'year': 2020, 'container_name': 'Nature', 'title': 'Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2', 'locator': None}
{'index': 39, 'target_release_id': None, 'extra': {'authors': ['KD Huebner'], 'doi': '10.1002/jor.22568', 'volume': '32'}, 'key': 'pmed.1003501.ref040', 'year': 2014, 'container_name': 'J Orthop Res', 'title': 'Dexamethasone inhibits inflammation and cartilage damage in a new model of post-traumatic osteoarthritis', 'locator': '566'}
{'index': 40, 'target_release_id': None, 'extra': {'authors': ['U Baschant'], 'doi': '10.1016/j.jsbmb.2010.03.058', 'issue': '2–3', 'volume': '120'}, 'key': 'pmed.1003501.ref041', 'year': 2010, 'container_name': 'J Steroid Biochem Mol Biol', 'title': 'The role of the glucocorticoid receptor in inflammation and immunity', 'locator': '69'}
{'index': 41, 'target_release_id': None, 'extra': {'authors': ['T Rhen'], 'doi': '10.1056/nejmra050541', 'issue': '16', 'volume': '353'}, 'key': 'pmed.1003501.ref042', 'year': 2005, 'container_name': 'N Engl J Med', 'title': 'Antiinflammatory action of glucocorticoids—new mechanisms for old drugs', 'locator': '1711'}
{'index': 42, 'target_release_id': None, 'extra': {'authors': ['JA Singh'], 'doi': '10.3899/jrheum.100717', 'volume': '38'}, 'key': 'pmed.1003501.ref043', 'year': 2011, 'container_name': 'J Rheumatol', 'title': 'Tocilizumab for rheumatoid arthritis: a Cochrane systematic review', 'locator': '10'}
{'index': 43, 'target_release_id': None, 'extra': {'authors': ['JS Smolen'], 'doi': '10.1016/s0140-6736(08)60453-5', 'issue': '9617', 'volume': '371'}, 'key': 'pmed.1003501.ref044', 'year': 2008, 'container_name': 'The Lancet', 'title': 'Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.', 'locator': '987'}
{'index': 44, 'target_release_id': None, 'extra': {'authors': ['A Sahraoui'], 'doi': '10.3727/096368913x667529', 'issue': '10', 'volume': '23'}, 'key': 'pmed.1003501.ref045', 'year': 2014, 'container_name': 'Cell Transplant', 'title': 'Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation', 'locator': '1199'}
{'index': 45, 'target_release_id': None, 'extra': {'authors': ['PA Nigrovic'], 'doi': '10.1002/art.30128', 'volume': '63'}, 'key': 'pmed.1003501.ref046', 'year': 2011, 'container_name': 'Arthritis Rheum', 'title': 'Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series', 'locator': '545'}
{'index': 46, 'target_release_id': None, 'extra': {'authors': ['S Yokota'], 'doi': '10.1016/s0140-6736(08)60454-7', 'issue': '9617', 'volume': '371'}, 'key': 'pmed.1003501.ref047', 'year': 2008, 'container_name': 'The Lancet', 'title': 'Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial', 'locator': '998'}
{'index': 47, 'target_release_id': None, 'extra': {'authors': ['RM Oates-Whitehead']}, 'key': 'pmed.1003501.ref048', 'year': 2003, 'container_name': 'Cochrane Database Syst Rev.', 'title': 'Intravenous immunoglobulin for the treatment of Kawasaki disease in children.', 'locator': None}
{'index': 48, 'target_release_id': None, 'extra': {'authors': ['RA Hughes'], 'doi': '10.1002/ebch.810'}, 'key': 'pmed.1003501.ref049', 'year': 2011, 'container_name': 'Evidence-Based Child Health: A Cochrane Review Journal.', 'title': 'Cochrane Review: Intravenous immunoglobulin for Guillain-Barré syndrome.', 'locator': '1176'}
{'index': 49, 'target_release_id': None, 'extra': {'authors': ['F Nimmerjahn'], 'doi': '10.1146/annurev.immunol.26.021607.090232', 'volume': '26'}, 'key': 'pmed.1003501.ref050', 'year': 2008, 'container_name': 'Annu Rev Immunol', 'title': 'Anti-inflammatory actions of intravenous immunoglobulin', 'locator': '513'}
{'index': 50, 'target_release_id': None, 'extra': {'authors': ['MM Alejandria']}, 'key': 'pmed.1003501.ref051', 'year': 2013, 'container_name': 'Cochrane Database Syst Rev', 'title': 'Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock', 'locator': None}
{'index': 51, 'target_release_id': None, 'extra': {'authors': ['F Khan']}, 'key': 'pmed.1003501.ref052', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections.', 'locator': None}
{'index': 52, 'target_release_id': None, 'extra': {'authors': ['C Qin']}, 'key': 'pmed.1003501.ref053', 'year': 2020, 'container_name': 'Clin Infect Dis', 'title': 'Dysregulation of immune response in patients with COVID-19 in Wuhan, China', 'locator': None}
{'index': 53, 'target_release_id': None, 'extra': {'authors': ['T Chen'], 'volume': '368'}, 'key': 'pmed.1003501.ref054', 'year': 2020, 'container_name': 'BMJ', 'title': 'Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.', 'locator': None}
{'index': 54, 'target_release_id': None, 'extra': {'authors': ['P Mehta'], 'doi': '10.1016/s0140-6736(20)30628-0', 'issue': '10229', 'volume': '395'}, 'key': 'pmed.1003501.ref055', 'year': 2020, 'container_name': 'Lancet (London, England).', 'title': 'COVID-19: consider cytokine storm syndromes and immunosuppression', 'locator': '1033'}
{'index': 55, 'target_release_id': None, 'extra': {'authors': ['X. Cao'], 'doi': '10.1038/s41577-020-0308-3', 'volume': '20'}, 'key': 'pmed.1003501.ref056', 'year': 2020, 'container_name': 'Nat Rev Immunol', 'title': 'COVID-19: immunopathology and its implications for therapy', 'locator': '269'}
{'index': 56, 'target_release_id': None, 'extra': {'authors': ['EC Somers']}, 'key': 'pmed.1003501.ref057', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'Tocilizumab for treatment of mechanically ventilated patients with COVID-19.', 'locator': None}
{'index': 57, 'target_release_id': None, 'extra': {'authors': ['R Rossotti'], 'doi': '10.1016/j.jinf.2020.07.008', 'volume': '81'}, 'key': 'pmed.1003501.ref058', 'year': 2020, 'container_name': 'J Infect.', 'title': 'Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.', 'locator': 'e11'}
{'index': 58, 'target_release_id': None, 'extra': {'authors': ['M Oray'], 'doi': '10.1517/14740338.2016.1140743', 'volume': '15'}, 'key': 'pmed.1003501.ref059', 'year': 2016, 'container_name': 'Expert Opin Drug Saf', 'title': 'Long-term side effects of glucocorticoids.', 'locator': '457'}
{'index': 59, 'target_release_id': None, 'extra': {'authors': ['CMP Jeronimo']}, 'key': 'pmed.1003501.ref060', 'year': 2020, 'container_name': 'Clin Infect Dis', 'title': 'Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.', 'locator': 'ciaa1177'}
{'index': 60, 'target_release_id': None, 'extra': {'authors': ['L Corral']}, 'key': 'pmed.1003501.ref061', 'year': 2020, 'container_name': 'MedRxiv.', 'title': 'GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia.', 'locator': None}
{'index': 61, 'target_release_id': None, 'extra': {'authors': ['Q Ma'], 'issue': '15', 'volume': '24'}, 'key': 'pmed.1003501.ref062', 'year': 2020, 'container_name': 'Eur Rev Med Pharmacol Sci', 'title': 'Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.', 'locator': '8194'}
{'index': 62, 'target_release_id': None, 'extra': {'authors': ['RC Group']}, 'key': 'pmed.1003501.ref063', 'year': 2020, 'container_name': 'N Engl J Med', 'title': 'Dexamethasone in hospitalized patients with Covid-19—preliminary report', 'locator': None}
{'index': 63, 'target_release_id': None, 'extra': {'authors': ['A Nikolakopoulou'], 'doi': '10.1136/bmj.k585', 'volume': '360'}, 'key': 'pmed.1003501.ref064', 'year': 2018, 'container_name': 'BMJ', 'title': 'Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study', 'locator': 'k585'}
{'index': 64, 'target_release_id': None, 'extra': {'authors': ['ES Rosenberg']}, 'key': 'pmed.1003501.ref065', 'year': 2020, 'container_name': 'JAMA', 'title': 'Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State', 'locator': None}
{'index': 65, 'target_release_id': None, 'extra': {'authors': ['NJ Mercuro'], 'doi': '10.1001/jamacardio.2020.1834'}, 'key': 'pmed.1003501.ref066', 'year': 2020, 'container_name': 'JAMA Cardiol.', 'title': 'Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19).', 'locator': '1036'}
{'index': 66, 'target_release_id': None, 'extra': {'authors': ['A Ramireddy'], 'doi': '10.1161/jaha.120.017144', 'issue': '12'}, 'key': 'pmed.1003501.ref067', 'year': 2020, 'container_name': 'J Am Heart Assoc', 'title': 'Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.', 'locator': 'e017144'}
{'index': 67, 'target_release_id': None, 'extra': {'authors': ['M Saleh']}, 'key': 'pmed.1003501.ref068', 'year': None, 'container_name': 'Circulation: Arrhythmia and Electrophysiology.', 'title': 'The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection.', 'locator': None}
{'index': 68, 'target_release_id': None, 'extra': {'authors': ['F Bessière'], 'doi': '10.1001/jamacardio.2020.1787'}, 'key': 'pmed.1003501.ref069', 'year': 2020, 'container_name': 'JAMA Cardiol.', 'title': 'Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit.', 'locator': '1067'}
{'index': 69, 'target_release_id': None, 'extra': {'authors': ['MGS Borba'], 'doi': '10.1001/jamanetworkopen.2020.8857'}, 'key': 'pmed.1003501.ref070', 'year': 2020, 'container_name': 'JAMA Netw Open', 'title': 'Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.', 'locator': 'e208857'}
{'index': 70, 'target_release_id': None, 'extra': {'authors': ['P Horby']}, 'key': 'pmed.1003501.ref071', 'year': 2020, 'container_name': 'medRxiv', 'title': 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.', 'locator': None}
{'index': 71, 'target_release_id': None, 'extra': {'authors': ['M Mahévas'], 'volume': '369'}, 'key': 'pmed.1003501.ref072', 'year': 2020, 'container_name': 'BMJ', 'title': 'Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data', 'locator': None}
{'index': 72, 'target_release_id': None, 'extra': {'authors': ['W Tang'], 'doi': '10.1136/bmj.m1849', 'volume': '369'}, 'key': 'pmed.1003501.ref073', 'year': 2020, 'container_name': 'BMJ', 'title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.', 'locator': 'm1849'}
{'index': 73, 'target_release_id': None, 'extra': {'authors': ['MH An']}, 'key': 'pmed.1003501.ref074', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea.', 'locator': None}
{'index': 74, 'target_release_id': None, 'extra': {'authors': ['DR Boulware']}, 'key': 'pmed.1003501.ref075', 'year': 2020, 'container_name': 'N Engl J Med', 'title': 'A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19', 'locator': None}
{'index': 75, 'target_release_id': None, 'extra': {'authors': ['CP Skipper'], 'doi': '10.7326/m20-4207', 'volume': '173'}, 'key': 'pmed.1003501.ref076', 'year': 2020, 'container_name': 'Ann Intern Med', 'title': 'Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial', 'locator': '623'}
{'index': 76, 'target_release_id': None, 'extra': {'authors': ['O Mitjà']}, 'key': 'pmed.1003501.ref077', 'year': 2020, 'container_name': 'Clin Infect Dis', 'title': 'Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial', 'locator': None}
{'index': 77, 'target_release_id': None, 'extra': {'authors': ['AB Cavalcanti']}, 'key': 'pmed.1003501.ref078', 'year': 2020, 'container_name': 'N Engl J Med', 'title': 'Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19', 'locator': None}
{'index': 78, 'target_release_id': None, 'extra': {'authors': ['O Mitja']}, 'key': 'pmed.1003501.ref079', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease.', 'locator': None}
{'index': 79, 'target_release_id': None, 'extra': {'authors': ['SM Lofgren']}, 'key': 'pmed.1003501.ref080', 'year': 2020, 'container_name': 'medRxiv.', 'title': 'Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19.', 'locator': None}
release_date 2020-12-30
release_stage published
release_type article-journal
release_year 2020
subtitle
title Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
version
volume 17
webcaptures
withdrawn_date
withdrawn_status
withdrawn_year
work_id b6gahpyd6rhtrfslxsfh7lbf44
As JSON via API

Extra Metadata (raw JSON)

crossref.subject ['General Medicine']
crossref.type journal-article
pubmed.pub_types ['Journal Article']